Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/157640
Full metadata record
DC FieldValueLanguage
dc.contributor.authorMoiola, Cristian P.-
dc.contributor.authorLopez Gil, Carlos-
dc.contributor.authorCabrera, Sílvia-
dc.contributor.authorGarcia, Angel-
dc.contributor.authorVan Nyen, Tom-
dc.contributor.authorAnnibali, Daniela-
dc.contributor.authorFonnes, Tina-
dc.contributor.authorVidal-Bel, August-
dc.contributor.authorVillanueva Garatachea, Alberto-
dc.contributor.authorMatias-Guiu, Xavier-
dc.contributor.authorKrakstad, Camilla-
dc.contributor.authorAmant, Frédéric-
dc.contributor.authorGil Moreno, Antonio-
dc.contributor.authorColás, Eva-
dc.date.accessioned2020-04-27T09:55:48Z-
dc.date.available2020-04-27T09:55:48Z-
dc.date.issued2018-08-17-
dc.identifier.issn1661-6596-
dc.identifier.urihttp://hdl.handle.net/2445/157640-
dc.description.abstractEndometrial cancer (EC) is the most common malignancy of the genital tract among women in developed countries. Recently, a molecular classification of EC has been performed providing a system that, in conjunction with histological observations, reliably improves EC classification and enhances patient management. Patient-derived xenograft models (PDX) represent nowadays a promising tool for translational research, since they closely resemble patient tumour features and retain molecular and histological features. In EC, PDX models have already been used, mainly as an individualized approach to evaluate the efficacy of novel therapies and to identify treatment-response biomarkers; however, their uses in more global or holistic approaches are still missing. As a collaborative effort within the ENITEC network, here we describe one of the most extensive EC PDX cohorts developed from primary tumour and metastasis covering all EC subtypes. Our models are histologically and molecularly characterized and represent an excellent reservoir of EC tumour samples for translational research. This review compiles the information on current methods of EC PDX generation and their utility and provides new perspectives for the exploitation of these valuable tools in order to increase the success ratio for translating results to clinical practice.-
dc.format.extent17 p.-
dc.format.mimetypeapplication/pdf-
dc.language.isoeng-
dc.publisherMDPI-
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.3390/ijms19082431-
dc.relation.ispartofInternational Journal of Molecular Sciences, 2018, vol. 19, num. 8, p. 2431-
dc.relation.urihttps://doi.org/10.3390/ijms19082431-
dc.rightscc-by (c) Moiola, Cristian P. et al., 2018-
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es-
dc.sourceArticles publicats en revistes (Patologia i Terapèutica Experimental)-
dc.subject.classificationCàncer d'endometri-
dc.subject.classificationAparell genital femení-
dc.subject.classificationMedicina personalitzada-
dc.subject.otherEndometrial cancer-
dc.subject.otherFemale generative organs-
dc.subject.otherPersonalized medicine-
dc.titlePatient-Derived Xenograft Models for Endometrial Cancer Research-
dc.typeinfo:eu-repo/semantics/article-
dc.typeinfo:eu-repo/semantics/publishedVersion-
dc.identifier.idgrec681592-
dc.date.updated2020-04-27T09:55:48Z-
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess-
dc.identifier.pmid30126113-
Appears in Collections:Articles publicats en revistes (Patologia i Terapèutica Experimental)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))

Files in This Item:
File Description SizeFormat 
681592.pdf1.16 MBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons